Zobrazeno 1 - 10
of 102
pro vyhledávání: '"A Margot Umpleby"'
Autor:
Emily Brown, Victoria S Sprung, Graham J Kemp, John PH Wilding, Malcolm Burgess, Daniel J Cuthbertson, A Margot Umpleby, Jason C G Halford, Andrej Stancak, Moon M Wilton, Joanne A Harrold, Elaine Howarth
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction The newer glucose-lowering therapies for type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), have additional clinical benefits beyond improving glyc
Externí odkaz:
https://doaj.org/article/e58426e12bf4422080cccd3ed1011943
Autor:
Ann Kristin Hjelle de Soysa, Mette Langaas, Anida Jakic, Fariba Shojaee-Moradie, A Margot Umpleby, Valdemar Grill, Ingrid Løvold Mostad
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0248247 (2021)
The objective of the study was to assess associations of the rs9939609 FTO allele to glucose tolerance, hepatic and total insulin sensitivity (IS) in individuals with obesity. From a low-dose hyperinsulinemic euglycemic clamp with glucose-tracer, hep
Externí odkaz:
https://doaj.org/article/0835acf76f1a4b7592280bc2d1cf5bbe
Autor:
Simon Steenson, Fariba Shojaee-Moradie, Martin B. Whyte, Kim G. Jackson, Julie A. Lovegrove, Barbara A. Fielding, A. Margot Umpleby
Publikováno v:
Nutrients, Vol 12, Iss 6, p 1781 (2020)
A high fructose intake exacerbates postprandial plasma triacylglycerol (TAG) concentration, an independent risk factor for cardiovascular disease, although it is unclear whether this is due to increased production or impaired clearance of triacylglyc
Externí odkaz:
https://doaj.org/article/2b747eb6cee44847a0f0e3ee3c010845
Autor:
Roselle A Herring, Iain Parsons, Fariba Shojaee-Moradie, Mary Stevenage, Nicola Jackson, Ralph Manders, A Margot Umpleby, Barbara A Fielding, Melanie Davies, David L Russell-Jones
Publikováno v:
The Journal of clinical endocrinology and metabolism.
Objective This work aimed to investigate the effect of the SGLT2 inhibitor, dapagliflozin (DAPA), on cardiac function and the metabolic and hormonal response to moderate exercise in people with type 2 diabetes. Methods This was a double-blind, placeb
Autor:
Roselle A. Herring, Fariba Shojaee-Moradie, Mary Stevenage, Iain Parsons, Nicola Jackson, Jeewaka Mendis, Benita Middleton, A. Margot Umpleby, Barbara A. Fielding, Melanie Davies, David L. Russell-Jones
OBJECTIVE To investigate the mechanism for increased ketogenesis following treatment with the SGLT2 inhibitor dapagliflozin in people with type 2 diabetes. RESEARCH DESIGN AND METHODS The design was a double-blind, placebo-controlled, crossover study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad87d3b8586448716427764d2c4729b
https://doi.org/10.2337/figshare.19241664
https://doi.org/10.2337/figshare.19241664
Autor:
Lucy Coppin, A. Margot Umpleby, Ewan R. Pearson, Nicola Jackson, Andrea Mari, Laura J. Mccreight
Publikováno v:
Diabetologia
Autor:
Barbara A. Fielding, Julie A. Lovegrove, Kim G. Jackson, Simon Steenson, A. Margot Umpleby, Fariba Shojaee-Moradie
Publikováno v:
Molecular Nutrition & Food Research. 66
Scope: Fructose exacerbates post-prandial hypertriacylglycerolaemia. This may be partly due to increased enterocyte de novo lipogenesis (DNL). It is unknown whether this is concentration-dependent or whether fructose has a greater effect on lipid syn
Autor:
Oluwatoyosi Bello, Fariba Shojaee-Moradie, Janet L. Peacock, Stephanie A. Amiel, Meera Ladwa, Louise M Goff, Riccardo C. Bonadonna, Olah Hakim, Maria Linda Boselli, A. Margot Umpleby
Publikováno v:
Acta diabetologica. 59(3)
Aim People of Black African ancestry, who are known to be at disproportionately high risk of type 2 diabetes (T2D), typically exhibit lower hepatic insulin clearance compared with White Europeans. However, the mechanisms underlying this metabolic cha
Autor:
Emily, Brown, Moon M, Wilton, Victoria S, Sprung, Joanne A, Harrold, Jason C G, Halford, Andrej, Stancak, Malcolm, Burgess, Elaine, Howarth, A Margot, Umpleby, Graham J, Kemp, John Ph, Wilding, Daniel J, Cuthbertson
Publikováno v:
BMJ Open
Introduction The newer glucose-lowering therapies for type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), have additional clinical benefits beyond improving glyc
Autor:
Victoria S. Sprung, John P.H. Wilding, Joanne A. Harrold, Emily Brown, Graham J. Kemp, Andrej Stancak, Moon Wilton, A. Margot Umpleby, Malcolm Burgess, Daniel J. Cuthbertson, Elaine Howarth, Jason C.G. Halford
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
IntroductionThe newer glucose-lowering therapies for type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the sodium-glucose co-transporter 2 inhibitors (SGLT2i), have additional clinical benefits beyond improving glyca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689d04f1ac6ac1d72d78432da97c8761